Dimebon was originally introduced as an antihistamine and subsequently investigated as a possible therapeutic for a variety of disorders, including Alzheimer's disease. One putative mechanism underlying the neuroprotective properties of Dimebon is inhibition of mitochondrial permeability transition, based on the observation that Dimebon inhibited the swelling of rat liver mitochondria induced by calcium and other agents that induce permeability transition. Because liver and brain mitochondria differ substantially in their properties and response to conditions associated with opening of the permeability transition pore, we sought to determine whether Dimebon inhibited permeability transition in brain mitochondria. Dimebon reduced calcium-induced mitochondrial swelling but did not enhance the calcium retention capacity or impair calcium-induced cytochrome C release from non-synaptic mitochondria isolated from rat brain cerebral cortex. These findings indicate that Dimebon does not inhibit mitochondrial permeability transition, induced by excessive calcium uptake, in brain mitochondria.
|Number of pages||6|
|State||Published - Mar 2011|
Bibliographical noteFunding Information:
Acknowledgments This research was supported by NIH grants PO1NS058484, PO1AG010836, R01NS062993, and P30NS051220, as well as funding from the Kentucky Spinal Cord and Head Injury Research Trust.
- Alzheimer's disease
- Cell death
ASJC Scopus subject areas
- Molecular Medicine
- Cellular and Molecular Neuroscience